MIR1257: A Drug Target / Disease Biomarker (G100302168)
MIR1257: A Drug Target / Disease Biomarker
MIR1257, also known as interleukin-1257, is a protein that is expressed in various tissues throughout the body, including the skin, eyes, and respiratory tract. It is a key regulator of immune responses and has been shown to play a role in the development and progression of various diseases, including cancer.
One of the most promising aspects of MIR1257 is its potential as a drug target. MIR1257 has been shown to interact with a variety of different proteins, including the immune checkpoint receptor PD-1. This suggests that MIR1257 could be a useful target for drugs that are designed to inhibit the activity of PD-1, which is a key regulator of immune responses.
In addition to its potential as a drug target, MIR1257 has also been shown to be a valuable biomarker for certain types of cancer. For example, studies have shown that MIR1257 levels are often elevated in the blood samples of patients with skin cancer, and that these levels can be used as a biomarker for the disease.
Another promising aspect of MIR1257 is its role in the regulation of cellular processes that are important for maintaining tissue health and function. For example, MIR1257 has been shown to play a role in the regulation of cell division and the production of new cells, which are important for the development and maintenance of tissues.
Overall, MIR1257 is a protein that has significant potential as a drug target and as a biomarker for certain types of cancer. Further research is needed to fully understand its role and potential applications in these fields.
Protein Name: MicroRNA 1257
The "MIR1257 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR1257 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR1258 | MIR125A | MIR125B1 | MIR125B2 | MIR126 | MIR1260A | MIR1260B | MIR1261 | MIR1262 | MIR1263 | MIR1264 | MIR1265 | MIR1266 | MIR1267 | MIR1268A | MIR1268B | MIR1269A | MIR1269B | MIR127 | MIR1270 | MIR1271 | MIR1272 | MIR1273A | MIR1273C | MIR1273H | MIR1275 | MIR1276 | MIR1277 | MIR1278 | MIR1279 | MIR128-1 | MIR128-2 | MIR1280 | MIR1281 | MIR1282 | MIR1283-1 | MIR1283-2 | MIR1284 | MIR1285-1 | MIR1285-2 | MIR1286 | MIR1287 | MIR1288 | MIR1289-1 | MIR1289-2 | MIR129-1 | MIR129-2 | MIR1290 | MIR1291 | MIR1292 | MIR1293 | MIR1294 | MIR1295A | MIR1295B | MIR1296 | MIR1297 | MIR1298 | MIR1299 | MIR1301 | MIR1302-1 | MIR1302-10 | MIR1302-11 | MIR1302-2 | MIR1302-3 | MIR1302-4 | MIR1302-5 | MIR1302-6 | MIR1302-7 | MIR1302-8 | MIR1302-9 | MIR1303 | MIR1304 | MIR1305 | MIR1306 | MIR1307 | MIR130A | MIR130B | MIR132 | MIR1321 | MIR1322 | MIR1323 | MIR1324 | MIR133A1 | MIR133A1HG | MIR133A2 | MIR133B | MIR134 | MIR1343 | MIR135A1 | MIR135A2 | MIR135B | MIR136 | MIR137 | MIR137HG | MIR138-1 | MIR138-2 | MIR139 | MIR140 | MIR141 | MIR142
